
    
      The study was stopped on 26 April 2013 due to feasibility issues (low enrollment) not safety.
      The overall risk-benefit of Lyrica has not changed at all due to termination of this trial.
      Only 9 of the 150 patients were enrolled into the trial, so we are unable to get adequate
      results from this study.
    
  